![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, July 13, 2007 8:51:35 PM
Then without the nm 283 catalyst acting on the stock price, the hbv drug would have gone through the same type of overexpectation mechanism, and underdelivery mechanism, of a market trying to settle on a fair value for a share of the underlying stock. thats my take on it, albeit at much lower mkt valuation than a company with two promising drug canditates ready to start procuding revenue.
nvs paying up for the license and jp somadosi buying a hundred grand worth of stock misled me into believing that the shorts were unaware of the seemingly evident.
live and learn...but i respect shorts way more.
May your investments prosper.Buy gold, it is money.http://images.sportsline.com/u/photos/baseball/mlb/img10422001.jpg
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM